Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SEMAGLUTIDE VERSUS GLP-1 RECEPTOR AGONISTS. EFFECTIVENESS , SAFETY AND QUALITY OF LIFE IN PATIENTS WITH DIABETES MELLITUS 2. OBSERVATIONAL, PROSPECTIVE AND MULTICENTER STUDY. SEVERAL STUDY.

NCT05136287 is registered in ClinicalTrials.gov with Jose Seijas Amigo as lead sponsor.

NCT NCT05136287
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05136287 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SEMAGLUTIDE VERSUS GLP-1 RECEPTOR AGONISTS. EFFECTIVENESS , SAFETY AND QUALITY OF LIFE IN PATIENTS WITH DIABETES MELLITUS 2. OBSERVATIONAL, PROSPECTIVE AND MULTICENTER STUDY. SEVERAL STUDY.
Lead sponsor
Jose Seijas Amigo
Phase
Observational
Overall status
Completed
Start date
February 1, 2022
Completion date
January 1, 2024
Enrollment
140 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus, type 2, quality of life, safety issues, weight loss